BioCryst’s voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signalsnews2022-05-05T14:21:59+00:00May 5th, 2022|FierceBiotech|
Big pharma resisting temptation for biotech M&A spree until prices drop furthernews2022-05-05T13:53:42+00:00May 5th, 2022|FierceBiotech|
Bavarian Nordic’s COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster pushnews2022-05-05T12:54:33+00:00May 5th, 2022|FierceBiotech|
Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospectnews2022-05-05T12:05:34+00:00May 5th, 2022|FierceBiotech|
BerGenBio shifts focus from COVID—to COVID in new business strategy updatenews2022-05-04T17:57:58+00:00May 4th, 2022|FierceBiotech|
Bancel has ‘never been as busy’ amid M&A talks as Moderna preps for life after COVIDnews2022-05-04T14:41:31+00:00May 4th, 2022|FierceBiotech|
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drugnews2022-05-04T14:24:39+00:00May 4th, 2022|FierceBiotech|
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug visionnews2022-05-04T13:28:16+00:00May 4th, 2022|FierceBiotech|
Catalio reloads with $381M after financing Octant, Pheastnews2022-05-04T13:23:18+00:00May 4th, 2022|FierceBiotech|
Biogen shoves Aduhelm to the side. It’s time for lecanemabnews2022-05-04T12:22:42+00:00May 4th, 2022|FierceBiotech|
